Avacta Group (AVCT.F) Stock Overview
Engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AVCT.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Avacta Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.74 |
| 52 Week High | UK£1.11 |
| 52 Week Low | UK£0.40 |
| Beta | -0.23 |
| 1 Month Change | -13.67% |
| 3 Month Change | n/a |
| 1 Year Change | 14.62% |
| 3 Year Change | -56.53% |
| 5 Year Change | -48.73% |
| Change since IPO | -48.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVCT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | 1.4% | -0.9% |
| 1Y | 14.6% | 27.5% | 12.5% |
Return vs Industry: AVCT.F underperformed the US Biotechs industry which returned 24% over the past year.
Return vs Market: AVCT.F exceeded the US Market which returned 11.2% over the past year.
Price Volatility
| AVCT.F volatility | |
|---|---|
| AVCT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVCT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AVCT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 151 | Chris Coughlin | avacta.com |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors.
Avacta Group Plc Fundamentals Summary
| AVCT.F fundamental statistics | |
|---|---|
| Market cap | US$308.69m |
| Earnings (TTM) | -US$54.51m |
| Revenue (TTM) | US$151.84k |
Is AVCT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCT.F income statement (TTM) | |
|---|---|
| Revenue | UK£113.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£113.00k |
| Other Expenses | UK£40.68m |
| Earnings | -UK£40.56m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.094 |
| Gross Margin | 100.00% |
| Net Profit Margin | -35,897.35% |
| Debt/Equity Ratio | 12,804.2% |
How did AVCT.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/21 03:19 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avacta Group Plc is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lorenza Castellon | Equity Development Limited |
| Julie Simmonds | Panmure Liberum |
| Julie Simmonds | Panmure Liberum |